Virtual Library
Start Your Search
Tahir Mehmood
Author of
-
+
P1.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies (ID 703)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.17-007 - Platinum Based Chemotherapy in Locally Advanced Non-Metastatic Thymic Carcinoma (ID 8821)
09:30 - 09:30 | Presenting Author(s): Tahir Mehmood
- Abstract
Background:
Thymic carcinoma is a rare malignant tumor. At present, cisplatin based doublet or triplet antitumor drugs are used in neo-adjuvant setting for advanced thymic carcinomas. However, no optimal chemotherapeutic regimen is well established and recent small case studies with carboplatin and paclitaxel doublet demonstrates the similar efficacy with less toxicity. We retrospectively evaluated effectiveness and toxicity of platinum based doublet chemotherapy for patients with advanced thymic carcinoma.
Method:
Between 2013 and 2016, we retrospectively identified 21 patients from hospital information system with pathologically confirmed advanced thymic carcinoma, who were treated with platinum based doublet chemotherapy followed by surgical resection. The most commonly used regimen being carboplatin plus docetaxel in 75% of the patients. Other regimens included cisplatin plus gemcitabine, carboplatin plus gemcitabine and cisplatin plus doxorubicin plus cyclophosphamide.
Result:
The clinical response rate was achieved in 61.5 % of the patients. The disease control rate was achieved in 92% of the patients. The median progression-free survival was 7.9 months (95% CI 1.3–10.0) and median overall survival was 33.8 months (95% CI 8.3–45.9). The toxicity profiles of platinum doublets demonstrated grade 3-4 hematological and non-hematological toxicities in 18% and 24% of the patients respectively. No febrile neutropenia and toxic death was recorded.
Conclusion:
We concluded that platinum doublet chemotherapy is active and tolerable for advanced thymic carcinoma in the front-line setting with regard to efficacy, toxicity, and usage in clinical setting.
-
+
P3.01 - Advanced NSCLC (ID 621)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-078 - Outcome of Stage IIIb Non-small Cell Lung Cancer (NSCLC) Patients – A Single Tertiary Center Experience (ID 8820)
09:30 - 09:30 | Presenting Author(s): Tahir Mehmood
- Abstract
Background:
The optimal treatment strategy for Stage IIIB NSCLC patients with a T4N0-1 tumor is a matter of debate. In prospective combined modality series including surgery, the median overall survival (OS) is approximately 24 months. We hypothesized that results comparable to regimens including surgery can be achieved with concurrent chemoradiation in this patient group.
Method:
In our retrospectively collected database of NSCLC patients, all patients with T4 (mediastinal invasion) N0-1 NSCLC receiving concurrent chemoradiation were included. One patient had a recurrence after previous pneumonectomy. All patients were given 3 cycles of chemotherapy (cisplatin and etoposide). Radiotherapy (RT) was started at the 2nd course of chemotherapy. OS was calculated from date of diagnosis (Kaplan-Meier method). Toxicity was scored according to CTCAEv3.0.
Result:
42 patients (8 female, 34 male) with a median age of 62.5 ± 9 years (44-80 years) were included from January 2005 until December 2009. Stage distribution: 86% T4N0 (n=36), 14% T4N1 (n=6). The maximal tumor dose was 66 Gy using conventional fractionation. The median prescribed mean lung dose was 15 ± 4.4 Gy (5.03 -19.9 Gy). Acute toxicity: 1 patient experienced grade 3 dyspnea during RT. Grade 3 dysphagia occurred in 5 patients (12%) during RT requiring tube feeding in 3 of these patients (7%). Dysphagia persisted later than 1 month after RT in 1 patient (2%). Grade 3 dysphagia only occurred in patients treated concurrently. Grade 3 cough occurred in 1 patient during RT, no patient experienced grade 3 cough 1 month after RT. 2 patients died within 3 months after start of RT, one due to myocardial infarction, one of unknown causes. Severe late toxicity was not present: no grade 3 complications more than 3 months after the end of radiotherapy. With a median follow-up of 42 months, the median OS for the whole group is 34 months (95% CI 24-43 months). 2-year OS survival is 55%.
Conclusion:
Concurrent accelerated chemoradiation using an individualized dose prescription is a valid treatment strategy for stage IIIb, T4N0-1 NSCLC patients yielding very promising OS results with low toxicity.
